Artivion Inc (NYSE: AORT) stock jumped 3.14% on Monday to $14.12 against a previous-day closing price of $13.69. With 0.14 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.23 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $14.23 whereas the lowest price it dropped to was $13.42. The 52-week range on AORT shows that it touched its highest point at $17.97 and its lowest point at $11.39 during that stretch. It currently has a 1-year price target of $24.15. Beta for the stock currently stands at 1.41.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AORT was up-trending over the past week, with a rise of 4.05%, but this was up by 7.46% over a month. Three-month performance dropped to -15.35% while six-month performance fell -6.24%. The stock gained 10.05% in the past year, while it has gained 16.50% so far this year. A look at the trailing 12-month EPS for AORT yields -0.60 with Next year EPS estimates of -0.03. For the next quarter, that number is -0.09. This implies an EPS growth rate of -54.58% for this year and 95.96% for next year.
Float and Shares Shorts:
At present, 40.34 million AORT shares are outstanding with a float of 39.00 million shares on hand for trading. On Oct 30, 2023, short shares totaled 2.8 million, which was 6.83% higher than short shares on Sep 28, 2023. In addition to Mr. James Patrick Mackin as the firm’s Chairman, President & CEO, Mr. David Ashley Lee CPA serves as its Executive VP, COO & CFO.
Through their ownership of 86.80% of AORT’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 44.69% of AORT, in contrast to 39.10% held by mutual funds. Shares owned by individuals account for 17.91%. As the largest shareholder in AORT with 14.87% of the stake, BlackRock Fund Advisors holds 6,104,146 shares worth 6,104,146. A second-largest stockholder of AORT, Macquarie Investment Management B, holds 2,886,666 shares, controlling over 7.03% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in AORT, holding 2,577,514 shares or 6.28% stake. With a 6.42% stake in AORT, the iShares Core S&P Small Cap ETF is the largest stakeholder. A total of 2,632,566 shares are owned by the mutual fund manager. The Delaware Small Cap Core Fund, which owns about 5.75% of AORT stock, is the second-largest Mutual Fund holder. It holds 2,359,339 shares valued at 30.06 million. Vanguard Total Stock Market ETF holds 2.74% of the stake in AORT, owning 1,123,317 shares worth 14.31 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AORT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With AORT analysts setting a high price target of $28.00 and a low target of $20.00, the average target price over the next 12 months is $24.15. Based on these targets, AORT could surge 98.3% to reach the target high and rise by 41.64% to reach the target low. Reaching the average price target will result in a growth of 71.03% from current levels.
Summary of Insider Activity:
Insiders traded AORT stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 51 while that of sell transactions has risen to 63 over the past year. The total number of shares bought during that period was 427,180 while 223,193 shares were sold.